Study the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects

Sponsor

VIVUS LLC (Industry)

Overall Status

Completed

CT.gov ID

NCT01095588

Collaborator

(none)

Enrollment

Arms

Duration (Days)

Study Details

Study Description

Brief Summary

This study is designed to look into the effect of avanafil on blood levels of warfarin and to investigate its effect on prothrombin time/international normalized ratio (INR) in healthy men.

Condition or Disease	Intervention/Treatment	Phase
Erectile Dysfunction	Drug: 200 mg Avanafil Drug: Placebo	Phase 1

Detailed Description

The trial is a single-centre, double-blind, randomized, placebo-controlled, 2-way crossover drug interaction study with at least a 21-day washout period.

Each subject will participate in two sessions in which they will be randomized to receive either 200 mg of avanafil or matching placebo for 9 days. On Day 3 of each period, subjects will receive a single dose of warfarin (25 mg). Following the warfarin dose, pharmacokinetic and pharmacodynamic sampling will be taken over a period of 7 days. Subjects will be discharged on Day 10 following the end-of-period evaluation. There will be a washout of at least 21 days between the warfarin doses. The study medications will be administered with 240 mL of water following an overnight fast of at least 10 hours.

Blood samples (3 mL) for the assessment of R- and S-warfarin concentrations in plasma will be drawn on Day 3 prior to warfarin administration and 0.5, 1, 1.5, 2, 4, 6, 9, 12, 24, 48, 72, 96, 120, 144, and 168 hours after the warfarin administration.

Blood samples (3 mL) for the assessment of avanafil and/or metabolite concentrations will be drawn on Day 3 prior to avanafil (or placebo) administration and at 0.5, 1, and 2 hours post-dose.

Blood samples (4.5 mL) for the assessment of prothrombin time (PT) and international normalized ratio (INR) will be drawn at screening, check-in, on Day 3 prior to warfarin administration and at 6, 12, 24, 36, 48, 72, 96, 120, 144, and 168 hours post-dose.

Blood samples (4.5 mL) for collagen-induced platelet aggregation will be drawn on Day 3 prior to warfarin administration and at 1, 4, 6, 12, and 24 hours post-dose.

A blood sample (8.5 mL) for VKORC1 and CYP2C9 genotyping will be drawn at the check-in for Period 1.

The overall blood volume required for this study (assuming direct venipuncture for each sample) will be approximately 446 mL.

All subjects will be confined at the Clinical Research Unit starting in on Day -2 for diet equilibration and will remain confined for approximately 24 hours following the last study drug administration on Day 9.

Adverse events, laboratory evaluations, electrocardiogram, physical examination, and vital signs will be assessed at various times during the study.

Study Design

Study Type:

Interventional

Actual Enrollment :

24 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Phase I, Single-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm Study of the Effects of Avanafil on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

Study Start Date :

Apr 1, 2010

Actual Primary Completion Date :

May 1, 2010

Actual Study Completion Date :

May 1, 2010

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Avanafil	Drug: 200 mg Avanafil 2 X 100mg tablets avanafil
Placebo Comparator: Placebo	Drug: Placebo 2 tablets

Arm

Intervention/Treatment

Experimental: Avanafil

Drug: 200 mg Avanafil

2 X 100mg tablets avanafil

Placebo Comparator: Placebo

Drug: Placebo

2 tablets

Outcome Measures

Primary Outcome Measures

Pharmacokinetics - PK parameters AUC, C-max and t-max of R-and S-warfarin [24 hrs]
Pharmacodynamics - Prothrombin time, INR values, and area under effect-time curve (AUEC) of prothrombin and INR on days 14 and 15 [24 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:

21 Years to 45 Years

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

adult male subjects,
21 to 45 years of age,
must be medically healthy with no clinically significant screening results.

Exclusion Criteria:

history or clinical evidence of clinically relevant cardiovascular (including thromboembolic disorders), hepatic, renal, hematological, endocrine, pulmonary, gastrointestinal, psychiatric or neurological impairment;
any clinically significant laboratory abnormalities as judged by the investigator;
systolic blood pressure < 90 or >120 mmHg;
diastolic blood pressure < 50 or > 90 mmHg;
allergy to or previous adverse events with PDE5 inhibitors, warfarin or their constituents;
use of prescription or over-the-counter drugs that are known to interfere with metabolism by the cytochrome P450 3A4 enzyme within 30 days of screening;
use of any investigational drug within 30 days of screening; use of any prescription or over-the-counter drugs or herbal remedies within 14 days of screening;
history of alcohol or drug abuse within 18 months, history of smoking within 6 months;
positive urine alcohol and drug test;
positive serum cotinine test;
positive serology for HIV, HCV, HBsAg.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

VIVUS LLC

Investigators

Study Director: Shiyin Yee, PhD, VIVUS LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

, ,

ClinicalTrials.gov Identifier:

NCT01095588

Other Study ID Numbers:

TA-016

First Posted:

Mar 30, 2010

Last Update Posted:

Jan 7, 2011

Last Verified:

Jan 1, 2011

Keywords provided by , ,

Additional relevant MeSH terms:

Erectile Dysfunction

Study Results

No Results Posted as of Jan 7, 2011